Ruthenium-Mediated 18F-Fluorination and Preclinical Evaluation of a New CB1 Receptor Imaging Agent [18F]FPATPP

Haaparanta-Solin M; Helin JS; López-Picón FR; Lahdenpohja S; Solin O; Kirjavainen A; Rajala N
Ruthenium-Mediated 18F-Fluorination and Preclinical Evaluation of a New CB1 Receptor Imaging Agent [18F]FPATPP

Haaparanta-Solin M
Helin JS
López-Picón FR
Lahdenpohja S
Solin O
Kirjavainen A
Rajala N
Katso/Avaa
Lataukset: 

ACS Publisher
doi:10.1021/acschemneuro.0c00313
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2021042826183
Tiivistelmä

Cannabinoid receptor 1 (CB1R) controls various physiological and pathological conditions, including memory, motivation, and inflammation, and is thus an interesting target for positron emission tomography (PET). Herein, we report a ruthenium-mediated radiolabeling synthesis and preclinical evaluation of a new CB1R specific radiotracer, [18F]FPATPP. [18F]FPATPP was produced with 16.7 ± 5.7% decay-corrected radiochemical yield and >95 GBq/μmol molar activity. The tracer showed high stability, low defluorination, and high specific binding to CB1Rs in mouse brain.

Kokoelmat